(NYSE: UBS) released its Q4 earnings in early February, beating the consensus estimates on both net revenues and adjusted net income, and also hinting at possible buyback increases throughout 2026. Despite that strength, the market seemingly didn’t like the report as the stock price closed >6% lower on the print.
On an underlying basis – excluding integration expenses – we see that UBS’s profit before tax hit $2.871 billion, and the management noted that there was $10.7 billion in cumulative cost savings, which looked very strong. Yet, the bank’s bottom line was also hit by a $457 million loss from repurchasing legacy Credit Suisse debt, so the quality of UBS’s earnings is driving the primary concern. In other words, the reported net profit growth of 56% relies heavily on the normalization of the cost base and, crucially, the management of legacy provisions.
A major part of the bank’s growth comes from releasing litigation reserves, which isn’t really a sustainable growth driver if we think about it for a while. Throughout 2025, UBS benefited from material net releases of provisions for litigation, regulatory, and similar matters, which effectively acted as a tailwind for the bottom line. If in Q3 2025 the bank saw a $668 million release in litigation reserves, by the end of Q4, the balance of provisions for litigation and regulatory matters had fallen to $2.200 billion (down from $3.096 billion just three months prior). I think UBS might be just using these releases to offset high integration costs and creating a veneer of prosperity that hides the true operational drag of the merger. At least that’s what it looks like to me.
The above-described reliance on non-recurring items brings the persistent issues of the Credit Suisse legacy into focus, and while UBS has successfully migrated about 85% of Swiss-booked accounts (per management’s commentaries), the integration remains one of the most complex in banking history. UBS will need to spend a total of $15 billion on integration by the end of 2026, and I think the migration of complex derivative positions carries substantial execution risk. It’s a wild card for investors because once all the adjustments disappear from the statements, UBS might not be able to repeat its current level of return on CET1 capital and NI margin.
Another concern that I have relates to the legal risks around the bank – part of them UBS inherited from Credit Suisse. For example, UBS remains embroiled in investigations regarding Archegos, the Mozambique “tuna bond” matter, and ongoing inquiries into Nazi-linked accounts that Credit Suisse allegedly maintained for decades (based on Reuters publication). UBS might have to spend billions in fines for what Credit Suisse was to blame for, and investors should always keep this in mind, in my view.
Also, what makes UBS particularly vulnerable to reputational shocks that can trigger client attrition among the ultra-high-net-worth (UHNW) segment is the bank’s selective compliance. A prime example here is the ongoing legal friction involving Russian-Uzbek billionaire Alisher Usmanov, who filed a lawsuit against UBS’s German unit after the bank filed several suspicious transaction reports that triggered investigations against Usmanov in Germany – claims that his legal team argued were unsubstantiated. While the related probe was later dropped, this case only confirms the dangerous vulnerability that UBS has because of its perceived abuse in its application of due diligence. Among recently published news, we also see that UBS banked Ghislaine Maxwell for years, moving her money after Epstein’s arrest. So, this perceived “selective enforcement” rather than uniform adherence to risk standards creates a “reality check” for investors, and it can make UBS trade cheaper to peers, hence giving limited upside potential for the post-Q4 dip buyers today.
As I’m writing these lines, UBS is trading at over 18x earnings multiple, and the bank has a market cap of $133.84 billion – it’s one of the biggest banks in Europe and the world. The problem is that even the biggest bank on the planet – JP Morgan (NYSE: JPM) trades at 14x earnings, being cheaper than UBS and having fewer fundamental and legal issues. I believe that UBS’s valuation appears increasingly precarious because it assumes a “perfect” regulatory environment. The current stock price reflects a 60%+ premium to tangible book value if we compare it to European banking stocks, which leaves almost no margin for error in an environment where capital market conditions remain volatile. That’s why UBS may reprice lower eventually – even a drop to 14x earnings multiple would result in stock price depreciation of over 22%.
In conclusion, while UBS Group AG has presented a facade of post-merger prosperity through its record $7 trillion in invested assets and a sharp YoY increase in net profit, this performance is heavily subsidized by the non-recurring release of litigation reserves and temporary tax benefits. The management’s “One Bank” concept is a powerful marketing tool, but the operational reality is one of a bank still cleaning its house while its most formidable competitors gain market share in the lucrative U.S. wealth market.
